Treatment of Low-Grade Bulbar Transitional Cell Carcinoma with Urethral Instillation of Mitomycin C
2008
Successful Treatment of Low-Grade Urethral Cancer with Mitomycin C
Sample size: 1
publication
Evidence: low
Author Information
Author(s): Emmanuel J. Melonakos, Richard A. Santucci
Primary Institution: Wayne State University
Hypothesis
Can Mitomycin C be effectively used to treat low-grade bulbar transitional cell carcinoma?
Conclusion
The patient is disease-free more than one year and three months post-treatment, demonstrating the effectiveness of this method.
Supporting Evidence
- The patient had multiple previous failures of treatment before this method.
- Mitomycin C is usually used for bladder cancer, not urethral cancer.
- The patient experienced typical side effects of Mitomycin but recovered from them.
Takeaway
A man with a rare type of cancer in his urethra was treated with a special medicine called Mitomycin C, and now he is healthy again.
Methodology
The patient received six weekly installations of Mitomycin C directly into the urethra using a special syringe.
Limitations
The study is based on a single case, limiting generalizability.
Participant Demographics
A 63-year-old male with recurrent low-grade bulbar urethral carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website